Key result
FMDV VP3 interacts with the transmembrane domain of MAVS to inhibit its mitochondria localization and aggregation, resulting in the suppression of the type-I interferon response.
Why the study?
Foot-and-mouth disease virus VP3 blocks the type-I interferon response by inhibiting MAVS mRNA expression, but the underlying mechanism was poorly understood.
FMDV VP3 suppresses the host type-I interferon response by directly interacting with the transmembrane domain of MAVS to prevent its mitochondrial localization and aggregation.
May inform FMDV countermeasures; leaves open in vivo validation and therapeutic translation.
As a structural protein of the Foot-and-mouth disease virus (FMDV), VP3 plays a vital role in virus assembly and inhibiting the interferon (IFN) signal transduction to promote FMDV replication. Previous studies demonstrated that FMDV VP3 blocks the type-I IFN response by inhibiting the mRNA expression of the mitochondrial antiviral-signaling protein (MAVS); however, the underlying mechanism is poorly understood. Here, we describe the specificity of FMDV VP3 interaction with the transmembrane (TM) domain of MAVS as FMDV driven type-I IFN inhibitory mechanism for its effective replication. The TM domain of MAVS governs the mitochondria localization of MAVS, and it is a key factor in type-I IFN signaling transduction via MAVS aggregation. Thereby, the interaction of FMDV VP3 with the TM domain of MAVS leads to the inhibition of MAVS mitochondria localization, self-association, and aggregation, resulting in the suppression of type-I IFN response. Collectively, these results provide a clear understanding of a key molecular mechanism used by the FMDV VP3 for the suppression of IFN responses via targeting MAVS.
No takes yet. Share an insight, caveat, or question.
Ekanayaka et al. (2021) studied Foot-and-mouth disease virus (FMDV) infection. FMDV VP3 was evaluated on Type-I interferon response and MAVS aggregation. FMDV VP3 interacts with the transmembrane domain of MAVS to inhibit its mitochondria localization and aggregation, resulting in the suppression of the type-I interferon response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: